Advertisement

Topics

Ablynx: ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

14:52 EDT 28 Jul 2017 | FinanzNachrichten

GHENT, Belgium, 26 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for caplacizumab, th...

Original Article: Ablynx: ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

NEXT ARTICLE

More From BioPortfolio on "Ablynx: ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...